Quick Answer
Moderna, Inc. reported Operating Income Loss of -$3.07 billion for the year ending 2025.
- Moderna, Inc. showed an increase of +22.1% in Operating Income Loss from 2024 to 2025.
- This data is from Moderna, Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$65.46 million | Q2 2017: -$94.19 million | Q3 2017: -$67.87 million | Q4 2017: -$41.83 million | Q1 2018: -$77.40 million | Q2 2018: -$97.02 million | Q3 2018: -$85.82 million | Q4 2018: -$153.03 million | Q1 2019: -$141.64 million | Q2 2019: -$143.71 million | Q3 2019: -$130.76 million | Q4 2019: -$130.56 million | Q1 2020: -$131.00 million | Q2 2020: -$122.00 million | Q3 2020: -$235.00 million | Q1 2021: $1.27 billion | Q2 2021: $3.06 billion | Q3 2021: $3.56 billion | Q1 2022: $4.23 billion | Q2 2022: $2.45 billion | Q3 2022: $1.17 billion | Q1 2023: -$366.00 million | Q2 2023: -$1.87 billion | Q3 2023: -$2.01 billion | Q1 2024: -$1.27 billion | Q2 2024: -$1.36 billion | Q3 2024: -$70.00 million | Q1 2025: -$1.05 billion | Q2 2025: -$907.00 million | Q3 2025: -$260.00 million.
- Over the full 10 years of available data (2016 to 2025), Moderna, Inc.'s Operating Income Loss has declined by 1,273.7%.
- Historical annual values: Fiscal year 2025: -$3.07 billion | Fiscal year 2024: -$3.95 billion | Fiscal year 2023: -$4.24 billion | Fiscal year 2022: $9.42 billion | Fiscal year 2021: $13.30 billion | Fiscal year 2020: -$763.00 million | Fiscal year 2019: -$546.00 million | Fiscal year 2018: -$413.27 million | Fiscal year 2017: -$269.36 million | Fiscal year 2016: -$223.77 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: